XML 151 R116.htm IDEA: XBRL DOCUMENT v3.21.1
Events after the reporting period (Details)
12 Months Ended
Feb. 09, 2021
USD ($)
Feb. 01, 2021
£ / shares
shares
Jan. 22, 2021
shares
Dec. 31, 2020
shares
Dec. 31, 2019
shares
Dec. 31, 2018
shares
Mar. 31, 2021
GBP (£)
Feb. 09, 2021
GBP (£)
shares
Feb. 09, 2021
$ / shares
Events after reporting period [Abstract]                  
Ordinary shares cancelled creating distributable reserve (in shares)       83,115 59,163 101      
Ordinary Shares [Member]                  
Events after reporting period [Abstract]                  
Ordinary shares cancelled creating distributable reserve (in shares)       163,870 45,581 10,950      
Growth Shares [Member]                  
Events after reporting period [Abstract]                  
Ordinary shares cancelled creating distributable reserve (in shares)       34,260 0 0      
Forecast [Member]                  
Events after reporting period [Abstract]                  
Ordinary shares cancelled creating distributable reserve (in shares)     6,414,412            
Forecast [Member] | GlaxoSmithKline [Member]                  
Events after reporting period [Abstract]                  
Target amount for release of deferred income | £             £ 3,208,000    
Forecast [Member] | Growth Shares [Member]                  
Events after reporting period [Abstract]                  
Shares converted (in shares)   1,926,000              
Forecast [Member] | Non-voting Ordinary Shares [Member]                  
Events after reporting period [Abstract]                  
Share conversion (in shares)   1              
Shares converted (in shares)   831,627              
Forecast [Member] | Deferred Shares [Member]                  
Events after reporting period [Abstract]                  
Share conversion (in shares)   3              
Shares converted (in shares)   4,349,000              
Forecast [Member] | Immunocore Holdings Limited [Member]                  
Events after reporting period [Abstract]                  
Share conversion (in shares)     0.01         0.01  
Share price (in pounds per share) | £ / shares   £ 0.002              
Funding costs including underwriter fee | $ $ 25,196,000                
Forecast [Member] | Immunocore Holdings Limited [Member] | Ordinary Shares [Member]                  
Events after reporting period [Abstract]                  
Share conversion (in shares)   1              
Shares issued in initial public offering (in shares)   20           11,426,280  
Par value per share (in pounds per share) | £ / shares   £ 0.0001              
Nominal value of ordinary shares | £               £ 23,000  
Forecast [Member] | Immunocore Holdings Limited [Member] | IPO [Member]                  
Events after reporting period [Abstract]                  
Proceeds from shares issued | $ 297,083,000                
Forecast [Member] | Immunocore Holdings Limited [Member] | ADS [Member]                  
Events after reporting period [Abstract]                  
Share price (in pounds per share) | $ / shares                 $ 26.00
Proceeds from shares issued | $ $ 15,000,000                
Additional ADS issued (in shares)               576,923  
Forecast [Member] | Immunocore Holdings Limited [Member] | Non-voting Ordinary Shares [Member]                  
Events after reporting period [Abstract]                  
Shares issued in initial public offering (in shares)   20              
Par value per share (in pounds per share) | £ / shares   £ 0.0001